The Leukaemia Research Group is lead by Professor Deb White and Cancer Theme Leader Professor Tim Hughes, and includes 20 members in three research teams : Genomics, Leukaemia and Clinical. The group conducts research in to the haematological malignancies chronic myeloid leukaemia (CML) and acute lymphoblastic leukaemia (ALL) in the areas of fundamental genomic discovery, developmental biology, translational research and innovative clinical trial development.
Research Background:

In the last decade there has been remarkable improvement in the treatment of chronic phase (CP) CML. CML is characterised by the Philadelphia Chromosome (Ph) resulting in the BCR-ABL1 oncogene. This encodes a tyrosine kinase, Bcr-Abl, that can be targeted by tyrosine kinase inhibitors (TKIs). However few CML patients (~20%) are cured with TKI therapy, and those treated with TKIs are likely to remain on them for life. Many patients will eventually achieve a stable complete molecular response (CMR) & approximately 40% of these patients can cease TKI therapy and remain in CMR, or treatment-free remission (TFR) long-term. Maximising the achievement of TFR represents one of the biggest challenges for CML clinicians today. The reasons for the remaining 60% of patients relapsing rapidly when TKI therapy is ceased remain undetermined, but likely hold the key to understanding and maximising TFR.

The Leukaemia Research Group is currently involved in the following diverse CML clinical trials :

• PINNACLE: newly diagnosed CP-CML patients treated with nilotinib in conjunction with Pegylated Interferon.
• ENESTswift: testing efficacy & safety of nilotinib in patients intolerant but responsive to other TKIs, with the aim to achieve a deeper molecular response.
• RESIST: a registry of CML patients in Australia & New Zealand and their change of therapies, most recently focusing on patients that are in a trial of cessation (TOC).
• DIRECT: newly diagnosed CML patients >60yrs of age treated with upfront dasatinib, a second generation TKI, with individualised dose optimization. (commencing early 2016).LENI: patients previously unsuccessful in a trial of imatinib cessation will restart imatinib for 12mths before combining it with lenalidomide (Revlimid®). The aim is to determine whether the combination will improve the likelihood of maintaining a treatment-free remission (TFR) and to assess the safety and tolerability of combination therapy. (commencing late 2015).

​Acute Lymphoblastic Leukaemia (ALL) is a malignant disorder of lymphoid progenitor cells that affects both children and adults, with initial diagnosis between the ages of 2 and 5 years, and a relapse often in older age groups. While cure rates exceed 80%, relapsed B cell precursor ALL remains a leading cause of non-traumatic death in children and adolescent/young adults (AYA). The outcomes in adults remain dire. Despite advances in therapy ALL is a fatal disease.

Treatment of Ph+ ALL with TKIs has remission rates of 90% but responses are short-lived with survival rates of 40-50%. Our aim is to interrogate drug sensitivity and mechanisms of drug resistance to develop personalised therapies. The current challenge is to identify robust and rapid biological markers of high risk ALL groups & re-purpose currently available therapies or develop new targeted therapies to treat patients with this high risk disease.

REGALLIA will be an Australia and New Zealand ALL registry commencing in early 2016 that this group will be involved with.

Professor John Hopwood and Professor Ian Frazer

The Aboriginal Diabetes Study Launch
The Aboriginal Diabetes Study is delighted and excited to announce and welcome celebrated actor Derik Lynch as our latest study Ambassador. The study already has fantastic supporters including Shelley Ware, Ruth Wallace and Andrea Mason. We are about to announce more Ambassadors soon who will help us spread the word that The Aboriginal Diabetes Study is set to launch on World Diabetes Day, November 14th at SAHMRI. Our new Facebook page for The Aboriginal Diabetes Study is already receiving lots of hits and anyone interested in taking part in the study can sign up via Facebook or our website at http://www.aboriginaldiabetes.com.  Together we can beat diabetes!

In-hospital communication with heart patients - can we do this better - The “Communicate” project
The “Communicate” project is funded through a Heart Foundation Focus Grant and is exploring the in-hospital communication and health literacy experiences of urban, rural and remote Aboriginal and Torres Strait Islander acute cardiac patients, their families and health care providers. It is being conducted in urban and regional settings in South Australia and the Northern Territory, specifically the Royal Adelaide Hospital, Port Augusta Hospital, Royal Darwin Hospital and Katharine Hospital.

Although in-hospital cardiac disparities for Aboriginal and Torres Strait Islander peoples are well reported, there is limited knowledge and understanding how health literacy and communication involving Aboriginal and Torres Strait Islander peoples can be enhanced during and following hospitalisation for cardiac events. Additionally while Aboriginal and Torres Strait Islander peoples who live in remote settings have a high likelihood of having health literacy issues, those who live in regional and urban settings may also be confronted by communication difficulties.

The project aims to better understand the current hospital experiences for Aboriginal and Torres Strait Islander patients, their families and health care providers, and identify barriers, enablers and potential improvements in written and oral communications between care providers, patients and their families throughout the journey. The project will make recommendations on strategies to improve the health literacy of patients and produce a resource to help health care providers better understand and respond to the experiences of Aboriginal and Torres Strait Islander cardiac patients and will be completed by June 2016.

Talking to the Aboriginal Community about Heart, Stroke and Diabetes Community Forum in the south 17th September 2015 - The development of two Health Policy Documents for Aboriginal people in South Australia: The Heart & Stroke Plan and the Whole of Health Diabetes Strategy

As part of the development of the SA Aboriginal Heart and Stroke Plan and the Whole of Health Diabetes Strategy for Aboriginal people in South Australia, a community forum took place on the 17th September 2015 at Christies Downs Community House. Aboriginal community members who have experienced diabetes and/or cardiovascular disease in the southern area were invited to actively be involved in mapping health services and the patient journey for Heart and Stroke and Diabetes care.

At the forum, participants identified issues of importance to the Southern Adelaide Aboriginal community, this included:

• Self-care for families should be supported
• Aboriginal people should have the option of self-referral via their primary health care provider for home care services
• Lack of heart and stroke related services in Southern Adelaide
• Need for education of signs and symptoms of heart and stroke events
• Individual and family stressors need to be understood by service providers
• Links with Aboriginal Health Workers
• Consider the impact of funding cuts which affect the availability of services
• Lack of identification of Indigenous people in hospitals still occurs – effects access to appropriate services
• Improved communication between service providers and patients in the hospital settings is needed
• A need for improved ability to deal with complex family situations which effects the health of Carers

It was very valuable to have an opportunity for the community to inform us of services that they access, or which they would like to be linked with. The information given at the Southern Adelaide Community Forum will be used to inform both the SA Aboriginal Heart and Stroke Plan and the Aboriginal Diabetes Strategy.
Other community forums are being held in Western, Northern and North Eastern Adelaide regions as well as country locations over the next few months.

Congratulations to HMBC/WCHRI PhD Graduates;  Lenka Malek, Philippa Middleton, Dominique Condo and Karen Best.  Best wishes in your chosen research fields.

HMBC/WCHRI’s international N3RO trial (N-3 fatty acids for the improvement of Respiratory Outcomes) has completed the recruitment phase with a total of 1273 babies which is slightly above the target outcome.  A fantastic outcome for all 13 sites.

HMBC/WCHRI ORIP trial (Omega 3 Fats to Reduce the Incidence of Prematurity) is almost half-way in the recruitment phase, with 2313 women currently participating and counting...  An enormous effort from all 6 sites.

Live Software Trial for Patient Recruitment in mental health studies 28th August 2015
Dr Mike Musker (SAHMRI Mind & Brain), Professor Niranjan Bidargaddi (Flinders University and SAHMRI fellow) and his team led a consumer meeting which completed a live trial of the goAct software that will be used as part of the Mind & Brain patient recruitment strategy.

Health Omnibus Research Collaboration 1st September 2015
The SAHMRI Mind & Brain Theme has become part of the next Health Omnibus Survey (HOS) study which interviews up to 5000 South Australians around a variety of health issues. Mind & Brain has joined the Health Omnibus Research Team this year which is a multi-institutional project including:
• PROS, Discipline of Medicine, University of Adelaide
• Discipline of General Practice, University of Adelaide
• Discipline of Obstetrics and Gynaecology, University of Adelaide
• Department of Health and Ageing, South Australia
• Cancer Council SA
• Drug and Alcohol Services of South Australia
• CSIRO Nutrition
• Carer’s Association
Dr Mike Musker presented about mental health, sex trauma, and bullying to the Harrison Research Group, the entity involved in delivering the Health Omnibus Survey

Resilient Futures Project Launch September 2015
The Mind & Brain Wellbeing and Resilience group has launched the Resilient Futures Project which involves building wellbeing in disadvantaged young people. The project has been funded at $1.232 million by the Wyatt Trust, The James and Diana Ramsay Foundation and the Department of Premier and Cabinet.

The Mind & Brain Wellbeing and Resilience group has initiated three pilot projects focused on Wellbeing and Ageing at a total cost of $343,000 funded by local councils, The Office for Health and Ageing and other investors.

Commercialisation International Summer School in Germany
Dr Martin Lewis (Mind & Brain) attended the 3rd International Summer School on Technology Transfer in Life Sciences at The Technische Universität Dresden.  This is a 5 day course covering identification of ideas, deciding on spin-off or licensing, protecting intellectual property, licensing, business model generation and practical venture capital for life sciences.

Prof Julio Licinio’s Invited Speaking Tour of Korea
Prof Julio Licinio (Mind and Brain Theme) was invited to visit Korea during September on a speaking tour. Prof Licinio gave the following 5 lectures at Ulsan University and Chonnam National University:
• 15th Sep 2015 – “Biomarkers of major depression.” Research Seminar presented at Ulsan University School of Medicine Department of Psychiatry, Asan Medical Centre, Seoul, South Korea.
• 15th Sep 2015 – “How to get published in the world's top medical research journals.” Research Seminar presented at Ulsan University School of Medicine, Department of Psychiatry, Asan Medical Centre, Seoul, South Korea.
• 17th Sep 2015 – “Biomarkers of major depression.” Research Seminar presented at Chonnam National University, Department of Psychiatry, Gwangju, South Korea.
• 17th Sep 2015 – “How to get published in the world's top medical research journals.” Research Seminar presented at Chonnam National University, Department of Psychiatry, Gwangju, South Korea.
• 18th Sep 2015 Licinio J. Major depression: An under-studied pathway from stress, obesity and leptin to mood and cognition. Keynote plenary presentation at the symposium Stress and Mental Disorders, Korean National Depression Translational Centre, Chonnam National University, Gwangju, South Korea

Prof Julio Licinio’s Invited Lectures at the University of New Mexico, Albuquerque, NM, USA, where he is a Clinical Professor of Psychiatry:
• 13th October 2015 – “The search for biomarkers of major depression and antidepressant treatment response.” Grand Rounds presented at the Department of Psychiatry, University of New Mexico School of Medicine.
• 16th October 2015 – “The interface of obesity and major depression: An under-studied pathway from stress, obesity, and leptin, to mood and cognition.” Presented at the Cellular and Molecular Basis of Disease Seminar Series, University of New Mexico School of Medicine.

Leading Light Award Keynote speaker
Professor Julio Licinio was keynote speaker at Leading Light Award 2015 on 29th September run by The Australian Society for Medical Research

The SAHMRI Research Showcase was held on 10th and 11th September, and was a great opportunity for staff and students to learn more about the research happening across Themes and Research Groups, both within the facility and at our external sites. Both days of the event were very well attended, with excellent opportunities presented for staff to meet and interact with other staff and students.

Our PhD students were given the opportunity to give a 3-minute lay summary of their research, with an award given for first place and runner up. Congratulations go to:

• Natasha Friend (Cancer) - First Place
• Lui Li (Cancer) - Runner Up

Awards were also given out to the first place and runner up posters. Congratulations go to:

• Kenneth Bryan (Infectiona and Immunity) - First Place
• Krzysztof Mrozik (Cancer) - Runner Up

We would like to thank all of those who assisted in the preparation of this very successful event.

The South Australian Academic Health Science and Translation Centre hosted a student open-night at SAHMRI on Monday 28th September. Representatives from the three SA Universities, SAHMRI and CSIRO attended, providing the opportunity for students to speak with them regarding higher degree opportunities, with a specific focus on translation.

The evening was very well attended, with over 200 students spending time meeting with staff and learning from the displays.

In addition to an Australian Postgraduate Award through University of Adelaide, Lauren Whyte in the Lysosomal Diseases Research Unit was awarded a top-up scholarship from Australian Rotary Health for her PhD project titled Risk factors for Alzheimer’s disease – does lysosomal dysfunction play a role?

Brown A, Mentha R, Howard M, Rowley K, Reilly R, Paquet C, et al. Men, hearts and minds: developing and piloting culturally specific psychometric tools assessing psychosocial stress and depression in central Australian Aboriginal men. Social psychiatry and psychiatric epidemiology. 2015:1-13.

The Echocardiographic Normal Ranges Meta-Analysis of the Left Heart Collaboration. Ethnic-Specific Normative Reference Values for Echocardiographic LA and LV Size, LV Mass, and Systolic Function. The EchoNoRMAL Study. JACC Cardiovascular Imaging. 2015;8(6):656-65 Micklem, Jasmine M. "Self-reported health-related quality-of-life issues for Aboriginal and Torres Strait Islander patients with experience of cancer in Australia: a review of literature." International journal of evidence-based healthcare (2015).

Campaniello M, Harrington AM, Martin C, Blackshaw LA, Brierley SM, Hughes PA. "Activation of colo-rectal high-threshold afferent nerves by Interleukin-2 is tetrodotoxin-sensitive and upregulated in a mouse model of chronic visceral hypersensitivity" Neurogastroenerology and Motility (accepted Sept. 2015)

Wong M-L, Dong C, Flores DL, Ehrhart-Bornstein M, Bornstein SR, Arcos-Burgos M, Licinio J. Clinical outcomes and genome-wide association for a brain methylation site in an antidepressant pharmacogenetics study in Mexican-Americans. American Journal of Psychiatry 2014;171:1297-1309.

BEARD H, HASSIOTIS S, LUCK AJ, ROZAKLIS T, HOPWOOD JJ, HEMSLEY KM.  Continual low-dose infusion of sulfamidase is superior to intermittent high-dose delivery in ameliorating neuropathology in the MPS IIIA mouse brain. (2015)   JIMD Reports  In press.

BEARD H, LUCK AJ, HASSIOTIS S, KING B, TRIM PJ, SNEL MF, HOPWOOD JJ, HEMSLEY KM.  Determination of the role of injection site on the efficacy of intra-CSF enzyme replacement therapy in MPS IIIA mice.  (2015)  Molec. Genet. Metab.  115: 33-44. 

FEDELE AO.  Sanfilippo syndrome: causes, consequences and treatments.  (2015)  Appl. Clin. Genet.  8: 1-13.

FERLA R, CLAUDIANI P, SAVARESE M, KOZARSKY K, HOPWOOD J, PARENTI G, FECAROTTA S, NIGRO V, SIVRI H, VAN DER PLOEG A, ANDRIA G, BRUNETTI-PIERRI N, AURICCHIO A.  Prevalence of anti-AAV8 neutralizing antibodies and ARSB cross-reactive immunologic material in MPS VI patients candidates for a gene therapy trial.  (2015)  Human Gene Therapy.  26: 145-152.

HOPWOOD J.  Prenatal diagnosis of the mucopolysaccharidoses and postnatal enzyme replacement therapy.  In: Genetic Disorders and the Fetus. (Milunsky A, ed), 7th ed.  John Wiley & Sons (2015) In press.

TRIM P, HOPWOOD J, SNEL M.  Butanolysis derivatization - Improved sensitivity in LC-MS/MS quantitation of heparan sulfate in urine from mucopolysaccharidosis patients.  (2015)  Anal. Chem. 

TURNER CT, FULLER M, HOPWOOD JJ, MEIKLE PJ, BROOKS DA.  Glycogen exocytosis from cultured Pompe skin fibroblasts. (2015)  Trans. Med.  6: 17.

Simonds SE, Pryor JT, Ravussin E, Greenway FL, Dileone R, Allen AM, Bassi J, Elmquist JK, Keogh JM, Henning E, Myers Jr MG, Licinio J, Brown RD, Enriori PJ, O’Rahilly S, Sternson SM, Spanswick DC, Grove JL, Farooqi IS, Cowley MA. Leptin mediates the increase in blood pressure associated with obesity. Cell 2014;159:1404-1416

Gold PW, Pavlatou MG, Michelson D, Mouro CM, Kling MA, Wong M-L, Licinio J, Goldstein SA. Chronic administration of anticonvulsants but not antidepressants impairs bone strength: clinical implications. Translational Psychiatry 2015;5:e576.  doi:10.1038/tp.2015.38.

Perry Y, Calear AL, Mackinnon AJ, Batterham PJ, Licinio J, King C, Thomsen N, Scott J, Donker T, Merry S, Fleming T, Stasiak K, Werner-Seidler A, Christensen H. Trial for the Prevention of Depression (TriPoD) in final year secondary students: study protocol for a cluster randomised controlled trial. Trials [in press].

Vélez JI, Lopera F, Sepulveda-Falla D, Patel HR, Johar AS, Chuah A, Tobón C, Rivera D, Villegas A, Cai Y, Peng K, Arkell R, Castellanos FX, De Leon J, Andrews SJ, Creagh PK, Easteal S, ML Wong M-L, Licinio J, Mastronardi CA, Arcos-Burgos M. APOE*E2 allele delays age of onset in PSEN1 E280A Alzheimer's disease. Molecular Psychiatry [in press].

Ullmann E, Barthel A, Tache S, Bornstein A, Licinio J, Bornstein SR. Emotional and psychological trauma in refugees arriving in Germany in 2015. Molecular Psychiatry 2015;20 [in press].

Huiping Yuan, Chenglong Yu, Liang Sun, Xiaoquan Zhu, Xinghui Li, Chenxiao Zhao, Zheng Zhang, Ze Yang. Serum uric acid levels and risk of metabolic syndrome: a dose-response meta-analysis of prospective studies, The Journal of Clinical Endocrinology & Metabolism 2015 [in press].

Vukićević V, Qin N, Balyura M, Eisenhofer G, Wong ML, Licinio J, Bornstein SR, Ehrhart-Bornstein M. Valproic acid enhances neuronal differentiation of sympathoadrenal progenitor cells. Molecular Psychiatry 2015 Aug; 20 (8) : 941-50. doi: 10.1038/mp.2015.3.

IL-17 producing mast cells promote the expansion of myeloid-derived suppressor cells in a mouse allergy model of colorectal cancer. Chen X, Churchill MJ, Nagar KK, Tailor YH, Chu T, Rush BS, Jiang Z, Wang EB, Renz BW, Wang H, Fung MC, Worthley DL, Mukherjee S, Wang TC. Oncotarget. 2015 Sep 26. [Epub ahead of print] 

Mucosally transplanted mesenchymal stem cells stimulate intestinal healing by promoting angiogenesis.Manieri NA, Mack MR, Himmelrich MD, Worthley DL, Hanson EM, Eckmann L, Wang TC, Stappenbeck TS. J Clin Invest. 2015 Sep 1;125(9):3606-18. doi: 10.1172/JCI81423. Epub 2015 Aug 17

Mist1 expressing gastric stem cells maintain the normal and neoplastic gastric epithelium and are supported by a distinct perivascular stem cell niche.   Hayakawa Y, Ariyama H, Stancikova J, Asfaha S, Renz BW, Dubeykovskaya ZA, Shibata W, Wang H, Westphalen CB, Chen X, Takemoto Y, Kim W, Khurana SS, Tailor Y, Nagar K, Tomita H, Hara A, Sepulveda AR, Setlik W, Gershon MD, Saha S, Ding L, Shen Z, Fox JG, Friedman RA, Konieczny SF, Worthley DL, Korinek V, Wang TC. Cancer Cell, 2015 in press

Palmer DJ, Sullivan T, Skeaff CM, Smithers LG, Makrides M on behalf of the DOMInO Allergy Follow up Team.  Higher cord blood 25-hydroxyvitamin D [25(OH)D] concentrations reduce the risk of early childhood eczema.  World Allergy Organisation Journal 2015;8:28

From e-pub to fully published
Gould JF, Anderson AJ, Yelland LN, Smithers LA, Skeaff M, Zhou SJ, Gibson RA, Makrides M.  Association of cord blood vitamin D levels at delivery with postpartum depression in Australian women.   Aust N Z J Obstet Gynaecol 2015;55:446-452. 

Malek L, Umberger W, Makrides M, Zhou SJ.  Adherence to the Australian dietary guideline during pregnancy: evidence from a national study.  Public Health Nutrition doi:10.1017/s1368980015002232  2015; Jul 31 (9 pages)  [Epub ahead of print]

Rankin W, Wittert G. Antiobesity drugs. Curr Opin Lipidol. 2015 Sep 18. [Epub ahead of print] PubMed PMID: 26382553.

Wittert GA, Huang KC, Heilbronn LK. Supporting the callout for people first
language in obesity. Obes Res Clin Pract. 2015 Jul-Aug;9(4):309. doi:10.1016/j.orcp.2015.08.008. PubMed PMID: 26373880.

Martin S, Vincent A, Taylor AW, Atlantis E, Jenkins A, Januszewski A, O'Loughlin P, Wittert G. Lower Urinary Tract Symptoms, Depression, Anxiety and Systemic Inflammatory Factors in Men: A Population-Based Cohort Study. PLoS One. 2015 Oct 7;10(10):e0137903. doi: 10.1371/journal.pone.0137903. eCollection 2015. PubMed PMID: 26445118.

Leiter LA, Astrup A, Andrews RC, Cuevas A, Horn DB, Kunešová M, Wittert G, Finer N. Identification of educational needs in the management of overweight and obesity: results of an international survey of attitudes and practice. Clin Obes. 2015 Oct;5(5):245-55. doi: 10.1111/cob.12109. Epub 2015 Aug 4. PubMed PMID: 26238414.

Tay J, Luscombe-Marsh ND, Thompson CH, Noakes M, Buckley JD, Wittert GA, Yancy WS Jr, Brinkworth GD. Comparison of low- and high-carbohydrate diets for type 2 diabetes management: a randomized trial. Am J Clin Nutr. 2015 Oct;102(4):780-90. doi: 10.3945/ajcn.115.112581. Epub 2015 Jul 29. PubMed PMID: 26224300.

Kentish SJ, Frisby CL, Kritas S, Li H, Hatzinikolas G, O'Donnell TA, Wittert GA, Page AJ. TRPV1 Channels and Gastric Vagal Afferent Signalling in Lean and High Fat Diet Induced Obese Mice. PLoS One. 2015 Aug 8;10(8):e0135892. doi:10.1371/journal.pone.0135892. eCollection 2015. PubMed PMID: 26285043; PubMed Central PMCID: PMC4540489.

Opolski M, Chur-Hansen A, Wittert G. The eating-related behaviours, disorders and expectations of candidates for bariatric surgery. Clin Obes. 2015 Aug;5(4):165-97. doi: 10.1111/cob.12104. PubMed PMID: 26173752.

For funding in mental health research, consider applying for a NARSAD Grant from the Brain & Behavior Research Foundation. For further information, go to the website.

The Nestle Nutrition Institute (NNI) South East Asia and Pacific Rim
(SEA&PR) Advisory Board will be launching a Young Researcher Award in 2016. The award will be based on a published or unpublished manuscript that is within the theme of “The first 1000 days of life”, with the first day of the first 1000 days being the day before conception. Thus the manuscript could relate to
pre-pregnancy, pregnancy, infancy or toddlers.

For further information about the application process please email Professor Peter Davies at ps.davies@uq.edu.au
For application cover sheet and submissions, please email Nestlé Nutrition Institute Australia at australia.nni@au.nestle.com

Closing date: Friday 18th December 2015.

27th November 2015

1:00pm - 2:00pm, SAHMRI Auditorium

Prof Renata Pasqualini, PhD and Prof Wadih Arap, MD, PhD from University of New Mexico, NM, USA.

Prof Pasqualini and Prof Arap have led a joint laboratory since October 1999 and published over 170 original peer-reviewed research manuscripts as a collaborative scientific effort. Over 110 patents have been filed worldwide, based on intellectual property developed in their laboratory, initially at The University of Texas, M. D. Anderson Cancer Center and currently at The University of New Mexico.  Their central working hypothesis is that normal or diseased tissues show differential protein expression in the human vascular endothelium, which offers the potential to develop novel diagnostic, imaging, and therapeutic strategies. The research program uses combinatorial peptide- and antibody-based library selection to discover, validate, and exploit the biochemical diversity of endothelial cell surface receptors to generate novel vascular-targeted pharmacologies. Translational applications of their work have led to the development of 2 first-in-man clinical trials. The Food and Drug Administration (FDA) granted “safe-to-proceed” status for their first vascular-targeted IND in 2009.This first-in-human study with a cohort of metastatic prostate cancer patients is complete and the results are in press. This trial successfully met drug localization and activity end points based on analyses of patient bone metastasis at multiple dose levels.  The filing of a second IND, also sponsored by philanthropy, is now an active Phase I study to evaluate an anti-obesity drug in castrate-resistant prostate patients with no standard treatment options. Two other drugs are in pre-IND stage, and several others are in the pre-clinical laboratory phase.  Long-term, the broader vision of our research is to generate a large-scale receptor map of the human vasculature.

15th-18th November 2015

Stamford Plaza, Adelaide

For registration visit http://www.asmr-nsc.org.au/   

Don’t miss out on a great scientific program, professional development workshops and networking opportunities.

Highlighted themes include: Gastrointestinal Microbiome, Gastrointestinal Cancers, Pancreatic and Liver Diseases, Gut Motility and Endocrinology, Inflammation and Immunity, Neurogastroenterology, Food and Nutrition

Further information will be provided in a future edition of the Bulletin.

Committee deadlines:

SA Health Human Research Ethics Committee
Proposals due: 16th November

RAH Human Research Ethics Committee
Proposals due: 9th November

QEH Human Research Ethics Committee
Proposals due: 11th November

WCH Human Research Ethics Committee
Proposals due: 18th November

Southern Adelaide Clinical Human Research Ethics Committee
Proposals due: 6th November

University of Adelaide HREC
Proposals due: 3rd November

University of South Australia HREC
Proposals due: 17th November

Flinders University Social and Behavioural Research Ethics CommitteeHREC
Proposals due: 16th November 

Aboriginal Health Research Ethics Committee
Proposals due: 19th November

SUBMISSION DATE             MEETING DATE
17th November                    1st December

Further information regarding the Committee can be found on the website. 

Next meeting - 3rd December

Further infomation can be found on the Committee website.

Gaining access - the process

The team at Bioresources is continually trying to improve and streamline training programs and make smoother access into the facility.  To clarify the new systems please head to our webpages.

In summary the following sessions/talks must be attended:

1. Ethics and Compliance talks, booked through Eventbrite, details of how to register can be found at the above link.
2. Bioresources Induction, every new user must undergo an induction into the facility. Induction training is the first Monday of each month at 3pm.
3. Other access Criteria (find details on website and book through PPMS)

• Emus training, to ensure you can use the mouse database.
• Animal handling assessment or training
• Humane Culling assessment or training
• Procedural techniques – assessment and training

(To arrange training, please book through PPMS under the Request Tab)

Supply of new wild-type lines

We are now able to supply the following wild-type line;

• BALB/cAnNCrl
• Sprague Dawley (Rats)

The colonies are new, and animal requests will need to be placed on Emus if you would like to use these strains. If you would like any advice or further information, do not hesitate to contact staff at Bioresources.

An update will be provided in a future Bulletin.

Updates will be provided in future editions of the newsletter.